Product Description: Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].
Applications: Cancer-Kinase/protease
Formula: C51H79NO13
References: [1]Zhang JW, et al. Metformin synergizes with rapamycin to inhibit the growth of pancreatic cancer in vitro and in vivo. Oncol Lett. 2018 Feb;15(2):1811-1816./[2]Niu H, et al. Rapamycin potentiates cytotoxicity by RP-56976 possibly through downregulation of Survivin in lung cancer cells. J Exp Clin Cancer Res. 2011 Mar 10;30:28./[3]Rangaraju S, et al. Rapamycin activates autophagy and improves myelination in explant cultures from neuropathicmice. J Neurosci. 2010 Aug 25;30(34):11388-97./[4]Edwards SR, et al. The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem, 2007, 282(18), 13395-13401.
CAS Number: 53123-88-9
Molecular Weight: 914.17
Compound Purity: 99.94
Research Area: Cancer
Solubility: DMSO : 125 mg/mL (ultrasonic)/Ethanol : 50 mg/mL (ultrasonic)
Target: Antibiotic;Autophagy;Bacterial;Endogenous Metabolite;FKBP;Fungal;mTOR
English
Deutsch
